GlassScriptPhysician profile
Abhitabh Patil
NPI 1346371085
$275,697.70
in general payments reported to CMS, 2019-2025
42 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $4,509 · 2021: $9,391 · 2022: $61K · 2023: $23K · 2024: $50K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $20K · Food and Beverage: $6,062 · Consulting Fee: $3,763 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,650.00 |
| Travel and Lodging | $19,744.08 |
| Food and Beverage | $6,061.95 |
| Consulting Fee | $3,762.96 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199,120.32 | 2019-2025 | |
| Wilson Cook Medical Incorporated | $57,162.00 | 2019-2025 | Fusion |
| Boston Scientific Corporation | $5,364.54 | 2019-2025 | General - Therapies, Spyglass, Cre Pro |
| Cook Medical LLC | $4,858.49 | 2019-2025 | Fusion, Hemospray, Echotip Insight |
| Ambu INC. | $4,233.10 | 2020-2024 | |
| Cook Incorporated | $2,000.00 | 2022 | |
| Janssen Biotech, INC. | $505.68 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $368.46 | 2019-2024 | Livdelzi |
| Celgene Corporation | $172.43 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $164.58 | 2019-2025 | Entyvio |
| Medical Device Business Services, INC. | $147.58 | 2023 | Linx Reflux Management System |
| Genzyme Corporation | $140.75 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $136.96 | 2022-2025 | |
| Medtronic, INC. | $128.05 | 2022-2023 | Endoflip |
| Intercept Pharmaceuticals, INC. | $113.26 | 2020-2025 | Ocaliva |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhitabh Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.